Navigation Links
Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting
Date:12/6/2010

SAN DIEGO, Dec. 6, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology (ASH), to be held on December 4-7 in Orlando, FL, the company announced today.  Kenna Anderes, VP Cancer Biology at Cylene, will discuss research on targeting CK2, a protein kinase that is essential for the progression of multiple myeloma but that has not been previously exploited as an anticancer target.  As the only CK2 inhibitor to have entered clinical trials, Cylene's pioneering compound, CX-4945, represents a promising new therapeutic approach to the treatment of this life-threatening blood cancer.

"The data from Kenna's lab demonstrates the importance of CK2 as a target for cancer therapeutics, validating our decision to move CX-4945 into humans.  We take pride both in being the first to take a CK2 compound into the clinic and in the recognition by ASH of the importance of this groundbreaking research," commented William G. Rice, PhD, President and CEO of Cylene Pharmaceuticals.  "The recently initiated trial in multiple myeloma is being conducted by Farnoush Abar, MD and Richard Maziarz, MD at the Oregon Health & Science University Knight Cancer Institute and by investigators who are part of the US Oncology Research nationwide network.  This trial is designed both to treat patients and simultaneously to expand our understanding of the precise role of CK2 in myeloma.  Molecular level characterization of patient samples alongside their response to CX-4945 will increase the likelihood that targeted treatment with CX-4945 will address this large unmet medical need."

The presentation schedule is:

Monday, December 6, 2010: 4:30 PM

Title: CX-4945, a Selective and Orally Biovailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κBSignaling and Induces Apoptosis in Multiple Myeloma Cells

Session: Myeloma – Pathophysiology and Preclinical Studies, excluding Therapy: Multiple Myeloma – Molecular Target-Based Therapy

Location: Orange County Convention Center, 314

About CK2 and CX-4945

Protein kinase CK2 has emerged as a validated drug target for cancer therapy due to its dysregulation andoverexpression in tumors and its regulatory roles in cell cycle control, DNA damage repair, and in the PI3K/Akt, JAK/STAT, IL-6 and NF-κB signaling cascades.  These pathways have specific relevance in multiple myeloma progression and high levels of CK2 overexpression characterize the disease.  CX-4945 is a potent and highly selective, small molecule inhibitor of CK2 and is currently under evaluation as an orally administered single agent in a Phase I clinical trial in patients with solid tumors (including breast, prostate, pancreatic cancers and inflammatory breast cancer) and a separate Phase I trial in patients with multiple myeloma has recently been initiated.  During the solid tumor trial, CX-4945 has established favorable pharmacokinetic, pharmacodynamic and safety profiles.  Measurement of mechanism and tumor-related biomarkers in patients reveal that CX-4945 hits the CK2 target and down-modulates the PI3K/Akt pathway.  The pharmacokinetic and biomarker data demonstrate that CX-4945 is achieving pharmacologically active levels in plasma and in tumor cells and elicits a clear pharmacodynamic response in humans.  Together, the findings establish CX-4945 as a promising therapeutic agent for targeting multiple cancers.

About Cylene Pharmaceuticals

Cylene Pharmaceuticals, Inc. is a San Diego-based, private biotechnology company, discovering and developing targeted small molecule drugs to treat life-threatening cancers.  Cylene's drug discovery platform, STAND (Selective TArgeting of Non-Oncogene Networks in Disease), has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support and maintenance of cancer cells and that address unmet medical needs with substantial markets.  Cylene's novel agents include oral inhibitors of the cancer-linked serine/threonine protein kinases (CK2 and Pim), as well as oral agents that activate p53 via modulation of RNA Polymerase I activity in the upstream ribosome biogenesis pathway.  Cylene's innovative platform enables the rapid discovery of first-in-class agents that exert antitumor activity as a single agent and that can mechanistically enhance the effectiveness of current cancer therapies.  For more information on Cylene and its programs, please visit www.cylenepharma.com.


'/>"/>
SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cylene to Present Advances with Industrys Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
2. Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
3. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
4. GENFIT Selected by Windhover for the 2011 Top Biopharma Projects To Watch
5. PolyOne GLS Selected as Healthcare Industry Marketing Specialist for Santoprene™ TPV Medical Grades
6. Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
7. CSA Medical Selected to Present at AdvaMed 2010: The MedTech Conference
8. The Colorado Institute for Drug, Device and Diagnostic Development Announces Companies Selected From Its First Solicitation: Sophono, Inc., Receiving $600K; and PeptiVir, Inc., $300K
9. Neuronetics Selected by World Economic Forum as 2011 Technology Pioneer
10. Greenway Selected by Health Information Exchanges and Regional Physician Groups
11. Award-Winning Thermal Angel Selected as Winner for Outstanding Military Product of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
Breaking Medicine Technology:
(Date:5/27/2016)... SC (PRWEB) , ... May 27, 2016 , ... ... a line of classic American timber frame barn kits, which can be found on ... are inspired by historic American barn plans, and they highlight the craftsmanship of timber ...
(Date:5/27/2016)... ... ... An influential resource amongst nurses and professionals in the health care world, ... of topics detailing why we appreciate nurses in so many different ways. From exclusive ... being in a major recession to one of the hottest growing professions in any ...
(Date:5/27/2016)... ... May 27, 2016 , ... An ... bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It ... leading advocates, associations and industry leaders such as Bioness. , As patients ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... installment is bolstered by inspiring human interest stories, courtesy of leaders in the ... and tech within the industry, from leading advocates and associations—namely Jones & Bartlett ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... the pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center ... proof of successfully certified products, services and staff. , Validation Center is ISO17025 ...
Breaking Medicine News(10 mins):